Physical chemistry of nanomedicine: Understanding the complex behaviors of nanoparticles in vivo

Annual Review of Physical Chemistry

Volumn 66, Issue , 2015, Pages 521-547

  Lane, Lucas A ^a   Qian, Ximei ^a   Smith, Andrew M ^b   Nie, Shuming ^a,c  

^a EMORY UNIVERSITY   (United States)

^b University of Illinois at Urbana Champaign   (United States)

^c NANJING UNIVERSITY   (China)

Author keywords

active targeting; antifouling; fluorescent dyes; image guided surgery; molecular imaging; oncology; passive targeting

Indexed keywords

BIOCHEMISTRY; CLINICAL RESEARCH; DIAGNOSIS; IMAGE ENHANCEMENT; INDIUM COMPOUNDS; MEDICAL NANOTECHNOLOGY; MOLECULAR IMAGING; NANOPARTICLES; PHYSICAL CHEMISTRY; PROTEINS; SURGERY; TARGETED DRUG DELIVERY;

ACTIVE TARGETING; ANTI-FOULINGS; CLINICAL APPLICATION; FLUORESCENT DYES; FUNDAMENTAL BARRIERS; IMAGE GUIDED SURGERY; IN-VIVO; INTERDISCIPLINARY FIELDS; MEDICAL DIAGNOSTICS; PASSIVE TARGETING;

CONTROLLED DRUG DELIVERY;

NANOPARTICLE; PROTEIN;

ANIMAL; CELL MEMBRANE; COMPUTER ASSISTED SURGERY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR IMAGING; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; PROTEINS; SURGERY, COMPUTER-ASSISTED;

EID: 84926505076     PISSN: 0066426X     EISSN: 15451593     Source Type: Book Series    
DOI: 10.1146/annurev-physchem-040513-103718     Document Type: Article

References (164)

1. West JL, Halas NJ. 2003. Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annu. Rev. Biomed. Eng. 5:285-92
2. Valiev R. 2002. Materials science: nanomaterial advantage. Nature 419:887-89
3. Whitesides GM. 2005. Nanoscience, nanotechnology, and chemistry. Small 1:172-79
4. Wagner V, Dullaart A, Bock A-K, Zweck A. 2006. The emerging nanomedicine landscape. Nat. Biotechnol. 24:1211-18
5. Liu Z, Cai W, He L, Nakayama N, Chen K, et al. 2007. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2:47-52
6. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. 2005. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23:1418-23
7. Lee ES, Na K, Bae YH. 2003. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 91:103-13
8. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-7
9. Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6:688-701
10. Couvreur P, Vauthier C. 2006. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23:1417-50
11. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53:283-318
12. Torchilin VP. 2007. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24:1-16
13. Babes L, Denizot B, Tanguy G, Le Jeune JJ, Jallet P. 1999. Synthesis of iron oxide nanoparticles used as MRI contrast agents: a parametric study. J. Colloid Interface Sci. 212:474-82
14. Laurent S, Forge D, Port M, Roch A, Robic C, et al. 2008. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108:2064-110
15. Rhyner MN, Smith AM, Gao XH, Mao H, Yang L, Nie SM. 2006. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine 1:209-17
16. Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, et al. 2007. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc. 2:1152-65
17. Wu X, LiuH, Liu J, Haley KN, Treadway JA, et al. 2003. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 21:41-46
18. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, et al. 2004. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22:93-97
19. Yezhelyev MV, Al-Hajj A, Morris C, Marcus AI, Liu T, et al. 2007. In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv. Mater. 19:3146-51
20. Liu J, Lau S, Varma V, Moffitt R, Caldwell M, et al. 2010. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano 4:2755-65
21. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. 2004. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22:969-76
22. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, et al. 2007. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. USA 104:2050-55
23. Lynch I, Dawson KA, Linse S. 2006. Detecting cryptic epitopes created by nanoparticles. Sci. Signal. 2006:pe14
24. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, et al. 2000. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18:301-13
25. Cedervall T, Lynch I, Foy M, Berggard T, Donnelly SC, et al. 2007. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. Engl. 46:5754-56
26. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. 2008. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. USA 105:14265-70
27. Vogel HG. 2002. Drug Discovery and Evaluation: Pharmacological Assays. Berlin: Springer-Verlag
28. Atkins PW, De Paula J. 2006. Atkins' Physical Chemistry. New York: Oxford Univ. Press
29. Astumian R, Schelly Z. 1984. Geometric effects of reduction of dimensionality in interfacial reactions. J. Am. Chem. Soc. 106:304-8
30. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. 2010. Time evolution of the nanoparticle protein corona. ACS Nano 4:3623-32
31. Rocker C, Potzl M, Zhang F, Parak WJ, Nienhaus GU. 2009. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat. Nanotechnol. 4:577-80
32. van Oss CJ. 2003. Long range and short range mechanisms of hydrophobic attraction and hydrophilic repulsion in specific and aspecific interactions. J. Mol. Recognit. 16:177-90
33. De Young LR, Fink AL, Dill KA. 1993. Aggregation of globular proteins. Acc. Chem. Res. 26:614-20
34. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. 2010. What the cell "sees" in bionanoscience. J. Am. Chem. Soc. 132:5761-68
35. Schowalter WR, Eidsath AB. 2001. Brownian flocculation of polymer colloids in the presence of a secondary minimum. Proc. Natl. Acad. Sci. USA 98:3644-51
36. Gessner A, Lieske A, Paulke BR, Muller RH. 2002. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm. 54:165-70
37. Vonarbourg A, Passirani C, Saulnier P, Benoit J-P. 2006. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27:4356-73
38. Luck M, Paulke BR, Schr oder W, Blunk T, Muller R. 1998. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39:478-85
39. Jeon S, Lee J, Andrade J, de Gennes P. 1991. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J. Colloid Interface Sci. 142:149-58
40. Lebovka NI. 2014. Aggregation of charged colloidal particles. In Polyelectrolyte Complexes in the Dispersed and Solid State I, ed. MMuller, pp. 57-96. New York: Springer
41. Manciu M, Ruckenstein E. 2001. Role of the hydration force in the stability of colloids at high ionic strengths. Langmuir 17:7061-70
42. Smith AM, Duan H, Mohs AM, Nie S. 2008. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60:1226-40
43. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, McGrath JL. 2009. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30:603-10
44. Dill KA, Truskett TM, Vlachy V, Hribar-Lee B. 2005. Modeling water, the hydrophobic effect, and ion solvation. Annu. Rev. Biophys. Biomol. Struct. 34:173-99
45. Brewer SH, Glomm WR, Johnson MC, Knag MK, Franzen S. 2005. Probing BSA binding to citratecoated gold nanoparticles and surfaces. Langmuir 21:9303-7
46. Kumar S, Nussinov R. 1999. Salt bridge stability in monomeric proteins. J. Mol. Biol. 293:1241-55
47. Walkey CD, Olsen JB, Song F, Liu R, Guo H, et al. 2014. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8:2439-55
48. Kairdolf BA, Mancini MC, Smith AM, Nie S. 2008. Minimizing nonspecific cellular binding of quantum dots with hydroxyl-derivatized surface coatings. Anal. Chem. 80:3029-34
49. Bretscher MS. 1975. Mammalian plasma membranes. Nature 258:43-49
50. Andrade J, Hlady V. 1986. Protein adsorption and materials biocompatibility: a tutorial review and suggested hypotheses. Adv. Polym. Sci. 79:1-63
51. Laughlin RG. 1991. Fundamentals of the zwitterionic hydrophilic group. Langmuir 7:842-47
52. He Y, Hower J, Chen S, Bernards MT, Chang Y, Jiang S. 2008. Molecular simulation studies of protein interactions with zwitterionic phosphorylcholine self-assembled monolayers in the presence of water. Langmuir 24:10358-64
53. Jiang S, Cao Z. 2010. Ultralow fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv. Mater. 22:920-32
54. Cao Z, Jiang S. 2012. Super-hydrophilic zwitterionic poly(carboxybetaine) and amphiphilic non-ionic poly(ethylene glycol) for stealth nanoparticles. Nano Today 7:404-13
55. Estephan ZG, Schlenoff PS, Schlenoff JB. 2011. Zwitteration as an alternative to PEGylation. Langmuir 27:6794-800
56. Hidalgo-Alvarez R, Mart A, Fernadez A, Bastos D, Martez F, de las Nieves F. 1996. Electrokinetic properties, colloidal stability and aggregation kinetics of polymer colloids. Adv. Colloid Interface Sci. 67:1-118
57. Leckband D. 2000. Measuring the forces that control protein interactions. Annu. Rev. Biophys. Biomol. Struct. 29:1-26
58. Gombotz WR, Guanghui W, Horbett TA, Hoffman AS. 1991. Protein adsorption to poly(ethylene oxide) surfaces. J. Biomed. Mater. Res. 25:1547-62
59. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. 1977. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252:3582-86
60. Allen T, Hansen C. 1991. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta Biomembr. 1068:133-41
61. Moghimi S, Szebeni J. 2003. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42:463-78
62. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, et al. 2007. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28:869-76
63. Kataoka K, Harada A, Nagasaki Y. 2001. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47:113-31
64. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. 2004. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22:969-76
65. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, et al. 2006. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control. Release 114:343-47
66. Lee H, Lee E, Kim DK, Jang NK, Jeong YY, Jon S. 2006. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J. Am. Chem. Soc. 128:7383-89
67. Ikada Y. 1984. Blood-compatible polymers. Adv. Polym. Sci. 57:103-40
68. Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, et al. 2011. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug. Chem. 22:976-86
69. Kopecek J, Kopeckov P. 2010. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 62:122-49
70. Kim K, Kim JH, Park H, Kim Y-S, Park K, et al. 2010. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 146:219-27
71. Mehvar R. 2000. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 69:1-25
72. Choi KY, Chung H, Min KH, Yoon HY, Kim K, et al. 2010. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31:106-14
73. Ishida T, Atobe K, Wang X, Kiwada H. 2006. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 115:251-58
74. Leger R, Arndt P, Garratty G, Armstrong J, Meiselman H, Fisher T. 2001. Normal donor sera can contain antibodies to polyethylene glycol (PEG). Transfusion 41:29S-30
75. Romberg B, Oussoren C, Snel CJ, Carstens MG, Hennink WE, Storm G. 2007. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochim. Biophys. Acta Biomembr. 1768:737-43
76. Chen KL, Bothun GD. 2013. Nanoparticles meet cell membranes: probing nonspecific interactions using model membranes. Environ. Sci. Technol. 48:873-80
77. Cho EC, Xie J, Wurm PA, Xia Y. 2009. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett. 9:1080-84
78. Chen H, Langer R, Edwards DA. 1997. A film tension theory of phagocytosis. J. Colloid Interface Sci. 190:118-33
79. Zhang M, Desai T, Ferrari M. 1998. Proteins and cells on PEG immobilized silicon surfaces. Biomaterials 19:953-60
80. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, A berg C. 2013. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135:1438-44
81. Ho K, Lapitsky Y, Shi M, Shoichet MS. 2009. Tunable immunonanoparticle binding to cancer cells: thermodynamic analysis of targeted drug delivery vehicles. Soft Matter 5:1074-80
82. MammenM, Choi S-K, WhitesidesGM. 1998. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. Engl. 37:2754-94
83. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM. 2007. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol. 14:107-15
84. Lu B, Smyth MR, O'Kennedy R. 1996. Tutorial review: oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Analyst 121:29R-32
85. Gantert M, Lewrick F, Adrian JE, Rossler J, SteenpaT, et al. 2009. Receptor-specific targeting with liposomes in vitro based on sterol-PEG1300 anchors. Pharm. Res. 26:529-38
86. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, et al. 2013. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8:137-43
87. Gu F, Zhang L, Teply BA, Mann N, Wang A, et al. 2008. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA 105:2586-91
88. Decuzzi P, Ferrari M. 2007. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 28:2915-22
89. Gao H, Shi W, Freund LB. 2005. Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA 102:9469-74
90. Conway A, Vazin T, Spelke DP, Rode NA, Healy KE, et al. 2013. Multivalent ligands control stem cell behaviour in vitro and in vivo. Nat. Nanotechnol. 8:831-38
91. Chithrani BD, Ghazani AA, Chan WC. 2006. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6:662-68
92. Cho EC, Zhang Q, Xia Y. 2011. The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotechnol. 6:385-91
93. Ruenraroengsak P, Novak P, Berhanu D, Thorley AJ, Valsami-Jones E, et al. 2012. Respiratory epithelial cytotoxicity and membrane damage (holes) caused by amine-modified nanoparticles. Nanotoxicology 6:94-108
94. Ginzburg VV, Balijepalli S. 2007. Modeling the thermodynamics of the interaction of nanoparticles with cell membranes. Nano Lett. 7:3716-22
95. Herce HD, Garcia AE. 2007. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. USA 104:20805-10
96. Yesylevskyy S, Marrink S-J, Mark AE. 2009. Alternative mechanisms for the interaction of the cellpenetrating peptides penetratin and the TAT peptide with lipid bilayers. Biophys. J. 97:40-49
97. Verma A, Uzun O, Hu Y, Hu Y, Han H-S, et al. 2008. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7:588-95
98. Van Lehn RC, Atukorale PU, Carney RP, Yang Y-S, Stellacci F, et al. 2013. Effect of particle diameter and surface composition on the spontaneous fusion of monolayer-protected gold nanoparticles with lipid bilayers. Nano Lett. 13:4060-67
99. Iversen T-G, Skotland T, Sandvig K. 2011. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6:176-85
100. Chithrani BD, Chan WC. 2007. Elucidating the mechanism of cellular uptake and removal of proteincoated gold nanoparticles of different sizes and shapes. Nano Lett. 7:1542-50
101. Jin H, Heller DA, Sharma R, Strano MS. 2009. Size-dependent cellular uptake and expulsion of singlewalled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 3:149-58
102. Iversen T-G, Frerker N, Sandvig K. 2010. Endocytosis and intracellular trafficking of quantum dot-ligand bioconjugates. In Organelle-Specific Pharmaceutical Nanotechnology, ed. V Weissig, GGM D'Souza, pp. 55-72. New York: Wiley
103. Lai SK, Hida K, Man ST, Chen C, Machamer C, et al. 2007. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 28:2876-84
104. HuY, Litwin T, Nagaraja AR, KwongB, Katz J, et al. 2007. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7:3056-64
105. Nishiyama N, Morimoto Y, Jang W-D, Kataoka K. 2009. Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv. Drug Deliv. Rev. 61:327-38
106. Decuzzi P, Ferrari M. 2008. The receptor-mediated endocytosis of nonspherical particles. Biophys. J. 94:3790-97
107. Ferrari M. 2008. Nanogeometry: beyond drug delivery. Nat. Nanotechnol. 3:131-32
108. Cho EC, Au L, Zhang Q, Xia Y. 2010. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small 6:517-22
109. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, et al. 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105:11613-18
110. Yang Q, Jones SW, Parker CL, Zamboni WC, Bear JE, Lai SK. 2014. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol. Pharm. 11:1250-58
111. Garg A, Tisdale AW, Haidari E, Kokkoli E. 2009. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366:201-10
112. Demirgoz DN, Garg A, Kokkoli E. 2008. PR-b-targeted PEGylated liposomes for prostate cancer therapy. Langmuir 24:13518-24
113. Sawant RR, Sawant RM, Kale AA, Torchilin VP. 2008. The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J. Drug Target. 16:596-600
114. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. 2003. In vivo fate of folatetargeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9:6551-59
115. Jain RK. 1987. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:559-93
116. Bhave G, Neilson EG. 2011. Body fluid dynamics: back to the future. J. Am. Soc. Nephrol. 22:2166-81
117. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, et al. 1999. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59:4129-35
118. Boucher Y, Jain RK. 1992. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52:5110-14
119. Iyer AK, Khaled G, Fang J, Maeda H. 2006. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11:812-18
120. Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:189-207
121. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. 1986. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46:3183-91
122. Khawli LA, Miller GK, Epstein AL. 1994. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 73:824-31
123. Sinha R, Kim GJ, Nie S, Shin DM. 2006. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5:1909-17
124. Stohrer M, Boucher Y, Stangassinger M, Jain RK. 2000. Oncotic pressure in solid tumors is elevated. Cancer Res. 60:4251-55
125. Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, et al. 2011. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc. Natl. Acad. Sci. USA 108:1799-803
126. Nagamitsu A, Greish K, Maeda H. 2009. Elevating blood pressure as a strategy to increase tumortargeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 39:756-66
127. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. 2000. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60:2497-503
128. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
129. Jain RK, Tong RT, Munn LL. 2007. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67:2729-35
130. McKee TD, Grandi P, Mok W, Alexandrakis G, InsinN, et al. 2006. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66:2509-13
131. Lammers T, Hennink W, Storm G. 2008. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99:392-97
132. Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60:1615-26
133. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. 2007. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104:15549-54
134. Huang X, Peng X, Wang Y, Wang Y, Shin DM, et al. 2010. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano 4:5887-96
135. Choi CHJ, Alabi CA, Webster P, Davis ME. 2010. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA 107:1235-40
136. Davis ME. 2009. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6:659-68
137. Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2:750-63
138. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, et al. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:4750-55
139. Albanese A, Lam AK, Sykes EA, Rocheleau JV, Chan WC. 2013. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat. Commun. 4:2718
140. Davis ME. 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7:771-82
141. Schrama D, Reisfeld RA, Becker JC. 2006. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5:147-59
142. Weiner LM, Adams GP. 2000. New approaches to antibody therapy. Oncogene 19:6144-51
143. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2:751-60
144. Romberg B, HenninkWE, Storm G. 2008. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25:55-71
145. Kale AA, Torchilin VP. 2007. Enhanced transfection of tumor cells in vivo using "smart" pH-sensitive TAT-modified pegylated liposomes. J. Drug Targeting 15:538-45
146. Schmaljohann D. 2006. Thermo-and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 58:1655-70
147. Sershen S, Westcott S, Halas N, West J. 2000. Temperature sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J. Biomed. Mater. Res. 51:293-98
148. Yavuz MS, Cheng Y, Chen J, Cobley CM, Zhang Q, et al. 2009. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat. Mater. 8:935-39
149. McBain SC, YiuHH, Dobson J. 2008. Magnetic nanoparticles for gene and drug delivery. Int. J. Nanomed. 3:169-80
150. Wilson MW, Kerlan RK Jr, Fidelman NA, Venook AP, LaBerge JM, et al. 2004. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite: initial experience with four patients. Radiology 230:287-93
151. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA. 2002. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Investig. Radiol. 37:580-86
152. Cheng R, Meng F, Deng C, Klok H-A, Zhong Z. 2013. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 34:3647-57
153. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. 2012. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903-10
154. Zhou K, Liu H, Zhang S, Huang X, Wang Y, et al. 2012. Multicolored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. J. Am. Chem. Soc. 134:7803-11
155. Wang Y, Zhou K, Huang G, Hensley C, Huang X, et al. 2014. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13:204-12
156. Sheridan C. 2012. Proof of concept for next-generation nanoparticle drugs in humans. Nat. Biotechnol. 30:471-73
157. Godin B, Tasciotti E, Liu X, Serda RE, Ferrari M. 2011. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 44:979-89
158. Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, et al. 2011. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. USA 108:2426-31
159. Chou LYT, Zagorovsky K, Chan WCW. 2014. DNA assembly of nanoparticle superstructures for controlled biological delivery and elimination. Nat. Nanotechnol. 9:148-55
160. Choi HS, Liu W, Liu F, Nasr K, Misra P, et al. 2009. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 5:42-47
161. Choi HS, Frangioni JV. 2010. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol. Imaging 9:291-310
162. Okusanya OT, Holt D, Heitjan D, Deshpande C, Venegas O, et al. 2014. Intraoperative near-infrared imaging can identify pulmonary nodules. Ann. Thorac. Surg. 98:1223-30
163. Holt D, Okusanya O, Judy R, Venegas O, Liang J, et al. 2014. Intraoperative near-infrared imaging can distinguish cancer from normal tissue but not inflammation. PLoS ONE 9:e103342
164. van Dam GM, Themelis G, Crane CMA, Harlaar NJ, Pleijhuis RG, et al. 2011. Intraoperative tumorspecific fluorescence imaging in ovarian cancer by folate receptor- targeting: first in-human results. Nat. Med. 17:1315-19